Observational studyBritish journal of clinical pharmacology2025
Metamizole induces voriconazole metabolism and results in subtherapeutic voriconazole concentrations.
Observational study in British journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Metamizole induces voriconazole metabolism and results in subtherapeutic voriconazole concentrations.British journal of clinical pharmacology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsVoriconazole is extensively metabolized via cytochrome P450 (CYP) enzymes, predominantly CYP2C19 and CYP3A4. Drugs influencing the activity or expression of CYP enzymes can cause clinically relevant changes in the metabolism and voriconazole exposure. Metamizole is known to induce CYP3A4 and CYP2C19. This study aimed to investigate the pharmacokinetic drug-drug interaction between metamizole and voriconazole.
methodsIn this single-centre retrospective observational cohort study, we compared voriconazole serum trough concentrations before, during and after metamizole treatment.
resultsIn the 9 included patients, the median voriconazole trough concentration decreased by 71% during metamizole treatment (P = .028) compared to before start of metamizole. The concentration/dose ratio similarly decreased by 81% during metamizole treatment (P = .018). Additionally, the metabolic ratio (voriconazole-n-oxide/voriconazole) increased from 0.9 to 2.4 (P = .028) during metamizole treatment. Subtherapeutic voriconazole trough concentrations were more frequent when combined with metamizole (before 14%, during 70%, after 17%).
conclusionsMetamizole increases voriconazole metabolism and decreases voriconazole trough concentrations, probably through a CYP3A4 and CYP2C19 inducing effect. It is recommended to avoid concurrent use of metamizole and voriconazole or to closely monitor voriconazole trough concentrations during metamizole treatment and up to 2 weeks after discontinuation of metamizole.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.